ES2090332T3 - Tejido linfoide humano en un hospedador inmunocomprometido. - Google Patents

Tejido linfoide humano en un hospedador inmunocomprometido.

Info

Publication number
ES2090332T3
ES2090332T3 ES91909374T ES91909374T ES2090332T3 ES 2090332 T3 ES2090332 T3 ES 2090332T3 ES 91909374 T ES91909374 T ES 91909374T ES 91909374 T ES91909374 T ES 91909374T ES 2090332 T3 ES2090332 T3 ES 2090332T3
Authority
ES
Spain
Prior art keywords
lymphoid tissue
immunocommitted
hospital
human
human lymphoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909374T
Other languages
English (en)
Inventor
Susan Mayo
Reiko Namikawa
Hideto Kaneshima
Joseph M Mccune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systemix Inc
Original Assignee
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systemix Inc filed Critical Systemix Inc
Application granted granted Critical
Publication of ES2090332T3 publication Critical patent/ES2090332T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Surgical Instruments (AREA)
  • Peptides Or Proteins (AREA)

Abstract

EL TEJIDO LINFOIDE HUMANO SE INTRODUCE EN UN HUESPED INMUNOCOMPROMETIDO PARA DAR LA OPORTUNIDAD DE INVESTIGAR EL EFECTO DE ESTIMULOS EN EL SISTEMA INMUNOLOGICO HUMANO Y OBTENER INFORMACION Y PRODUCTOS PARA EL ESTIMULO. SE PRESENTA, DE MANERA PARTICULAR, LA METODOLOGIA PARA LA PRODUCCION DE ANTICUERPOS MONOCLONALES HUMANOS MEDIANTE LA INTRODUCCION DE TEJIDO LINFOIDE EN UN HUESPED INMUNOCOMPROMETIDO, ESTIMULANDO LOS LINFOCITOS B CON UN INMUNOGEN APROPIADO, RECOGIENDO EL TEJIDO E INMORTALIZANDO Y/O CLONANDO LOS LINFOCITOS B BAJO CONDICIONES CAPACES DE PROPORCIONAR UN SUMINISTRO ESTABLE DE ANTICUERPOS MONOCLONALES.
ES91909374T 1990-05-03 1991-04-29 Tejido linfoide humano en un hospedador inmunocomprometido. Expired - Lifetime ES2090332T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51874890A 1990-05-03 1990-05-03

Publications (1)

Publication Number Publication Date
ES2090332T3 true ES2090332T3 (es) 1996-10-16

Family

ID=24065324

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909374T Expired - Lifetime ES2090332T3 (es) 1990-05-03 1991-04-29 Tejido linfoide humano en un hospedador inmunocomprometido.

Country Status (11)

Country Link
US (1) US5411749A (es)
EP (1) EP0481058B1 (es)
JP (1) JPH04507109A (es)
AT (1) ATE140480T1 (es)
AU (1) AU637914B2 (es)
CA (1) CA2063408A1 (es)
DE (1) DE69120890T2 (es)
DK (1) DK0481058T3 (es)
ES (1) ES2090332T3 (es)
GR (1) GR3021382T3 (es)
WO (1) WO1991016910A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849288A (en) * 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
US5652373A (en) * 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
DK9091D0 (da) * 1991-01-18 1991-01-18 Novo Nordisk As Fremgangsmaade til fremstilling af antistoffer
US5849987A (en) * 1992-06-02 1998-12-15 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
US5858328A (en) * 1991-06-04 1999-01-12 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
US5804160A (en) * 1991-06-04 1998-09-08 Yeda Research And Development Co. Ltd Animal model for hepatitis virus infection
DE69229254T2 (de) * 1991-10-30 1999-09-23 Idemitsu Kosan Co. Ltd., Tokio/Tokyo Verfahren zur Herstellung von menschlichen Lymphozyten und menschlichen Antikörpern; und so hergestellte Antikörper
US5866757A (en) * 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
CA2144314A1 (en) * 1992-09-11 1994-03-31 James M. Wilson Non-human animal with xenograft of on airway populated by human cells
CA2103693A1 (en) * 1993-08-06 1995-02-07 Steven Gallinger Animal model of the human immune system
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
US5516977A (en) * 1993-12-17 1996-05-14 Systemix, Inc. Xenogeneic tissue implant in ear pinna
US6455756B1 (en) * 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
CA2205138A1 (en) * 1994-11-16 1996-05-23 Baxter International Inc. Human antibodies to t-cell receptor peptides and methods for their preparation
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US5986170A (en) * 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
WO1998044788A2 (en) * 1997-04-09 1998-10-15 Chang Lung Ji Animal model for evaluation of vaccines
DK1265928T3 (da) * 2000-01-27 2010-11-15 Medimmune Llc RSV-neutraliserende antistoffer med ultra høj affinitet
EP1259547B1 (en) 2000-03-01 2012-07-11 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CA2542232A1 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
US20060115485A1 (en) * 2004-10-29 2006-06-01 Medimmune, Inc. Methods of preventing and treating RSV infections and related conditions
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
DK3056082T3 (en) 2009-10-06 2018-12-17 Regeneron Pharma RE-MODIFIED MICE AND INPUT
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US20110229921A1 (en) * 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
WO2011163558A1 (en) 2010-06-25 2011-12-29 Abbott Laboratories Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
EP2675271B1 (en) 2011-02-15 2018-06-13 Regeneron Pharmaceuticals, Inc. Humanized m-csf mice
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
AU2013312359B8 (en) 2012-09-07 2019-08-15 Institute For Research In Biomedicine (Irb) Genetically modified non-human animals and methods of use thereof
SG11201502685XA (en) 2012-11-05 2015-05-28 Regeneron Pharma Genetically modified non-human animals and methods of use thereof
SG10202002187WA (en) 2014-05-19 2020-04-29 Regeneron Pharma Genetically modified non-human animals expressing human epo
IL302370B2 (en) 2015-04-13 2025-10-01 Regeneron Pharma Mice genetically engineered to express alpha signal modulator protein and interleukin 15 and methods for using them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE119197T1 (de) * 1987-12-23 1995-03-15 Univ Leland Stanford Junior Schimäre immunkompromittierende säugetiere und ihre verwendung.
JP2981486B2 (ja) * 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
EP0438053B1 (en) * 1990-01-15 1999-06-16 Yeda Research And Development Company Limited Durable engraftment and development of human hematopoietic lineages in normal mammals
WO1991018615A1 (en) * 1990-05-25 1991-12-12 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
JPH04252128A (ja) * 1990-08-03 1992-09-08 Systemix Inc 免疫化された宿主における変性された異種移植器官系

Also Published As

Publication number Publication date
EP0481058B1 (en) 1996-07-17
AU7858391A (en) 1991-11-27
US5411749A (en) 1995-05-02
AU637914B2 (en) 1993-06-10
GR3021382T3 (en) 1997-01-31
CA2063408A1 (en) 1991-11-04
EP0481058A1 (en) 1992-04-22
ATE140480T1 (de) 1996-08-15
WO1991016910A1 (en) 1991-11-14
JPH04507109A (ja) 1992-12-10
DE69120890T2 (de) 1997-02-20
DE69120890D1 (de) 1996-08-22
DK0481058T3 (da) 1996-12-02
EP0481058A4 (en) 1993-07-14

Similar Documents

Publication Publication Date Title
ES2090332T3 (es) Tejido linfoide humano en un hospedador inmunocomprometido.
DE69429625D1 (de) Dämpfung eines immundominanten epitops eines antigens zur verwendung für pflanzen, tierische und menschliche impstoffe und immuntherapien
DE68924162D1 (de) Stressproteine und verwendungen dafür.
DE69329503D1 (de) Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
EP0474727A4 (en) Her2 extracellular domain
ATE154642T1 (de) Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
ES2145004T3 (es) Derivados de anticuerpos.
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
NO933126D0 (no) Loeselige ligander for cd40
ATE127694T1 (de) Lebende impfstoffe.
ATE237351T1 (de) Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
EP0570583A4 (en) ACTIVE SUBSTANCE FOR HAIR MODIFICATION AND HAIR CARE PRODUCT, WHICH CONTAIN BOTH AN ANTI-KERATINE ANTIBODY, AND PRODUCTION OF THE ANTI-KERATINE ANTIBODY.
EP0668772A4 (en) SPECIFIC MODULATIONS OF THE IMMUNE SYSTEM.
ATE101648T1 (de) Expression eines tumorspezifischen antigens eines rekombinanten virusvektors sowie dessen anwendung zur versorgenden oder heilenden behandlung des entsprechenden tumors.
GR3029774T3 (en) Method of preparing a radioactive rhenium complex solution.
DK16087D0 (da) Mastitis-vaccine
DE69022980D1 (de) Gesteigerte erzeugung von proteinen in tieren.
GR3021983T3 (en) Cross-reactive influenza a immunization
Devyataev et al. Selective effect of sensitization on the phenotype of slow and fast skeletal muscle of guinea pig
Umnyashkin Experience of neuroleptic-resistant schizophrenia treatment
Guseva et al. The choice of tactics of immunocorrecting therapy in patients with chronic leukaemias
Abdullayev Psychotropic preparations and immune system
ES2038578T1 (es) Utilizacion de inmunoglobulinas g humanas, o de fragmentos fc de estas, como medicamento preparatorio para la administracion al hombre de anticuerpos monoclonales.
BG50103A1 (en) Hybridome cell line, secretting monoclonal antibody against antigene determinante noc- 2 of malignant melanom in human

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 481058

Country of ref document: ES

FG2A Definitive protection

Ref document number: 481058

Country of ref document: ES